Loading...

Intellia Therapeutics

Nasdaq:NTLA
Snowflake Description

Excellent balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
NTLA
Nasdaq
$711M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The last earnings update was 18 days ago. More info.


Add to Portfolio Compare Print
NTLA Share Price and Events
7 Day Returns
3.9%
NasdaqGM:NTLA
-1.6%
US Biotechs
-0.7%
US Market
1 Year Returns
-36.1%
NasdaqGM:NTLA
-5.5%
US Biotechs
3%
US Market
NTLA Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Intellia Therapeutics (NTLA) 3.9% -3.7% 13.5% -36.1% -45% -
US Biotechs -1.6% -5.5% -6.5% -5.5% 9.7% 12%
US Market -0.7% -2% 2.4% 3% 39.2% 42%
1 Year Return vs Industry and Market
  • NTLA underperformed the Biotechs industry which returned -5.5% over the past year.
  • NTLA underperformed the Market in United States of America which returned 3% over the past year.
Price Volatility
NTLA
Industry
5yr Volatility vs Market
Related Companies

NTLA Value

 Is Intellia Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Intellia Therapeutics. This is due to cash flow or dividend data being unavailable. The share price is $15.55.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Intellia Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Intellia Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:NTLA PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $-1.96
NasdaqGM:NTLA Share Price ** NasdaqGM (2019-05-17) in USD $15.55
United States of America Biotechs Industry PE Ratio Median Figure of 34 Publicly-Listed Biotechs Companies 19.48x
United States of America Market PE Ratio Median Figure of 3,088 Publicly-Listed Companies 17.89x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Intellia Therapeutics.

NasdaqGM:NTLA PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:NTLA Share Price ÷ EPS (both in USD)

= 15.55 ÷ -1.96

-7.94x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Intellia Therapeutics is loss making, we can't compare its value to the US Biotechs industry average.
  • Intellia Therapeutics is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Intellia Therapeutics's expected growth come at a high price?
Raw Data
NasdaqGM:NTLA PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -7.94x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts
-21.3%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 27 Publicly-Listed Biotechs Companies 1.32x
United States of America Market PEG Ratio Median Figure of 2,117 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Intellia Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Intellia Therapeutics's assets?
Raw Data
NasdaqGM:NTLA PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $5.81
NasdaqGM:NTLA Share Price * NasdaqGM (2019-05-17) in USD $15.55
United States of America Biotechs Industry PB Ratio Median Figure of 416 Publicly-Listed Biotechs Companies 3.21x
United States of America Market PB Ratio Median Figure of 5,195 Publicly-Listed Companies 1.83x
NasdaqGM:NTLA PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:NTLA Share Price ÷ Book Value per Share (both in USD)

= 15.55 ÷ 5.81

2.68x

* Primary Listing of Intellia Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Intellia Therapeutics is good value based on assets compared to the US Biotechs industry average.
X
Value checks
We assess Intellia Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Intellia Therapeutics has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

NTLA Future Performance

 How is Intellia Therapeutics expected to perform in the next 1 to 3 years based on estimates from 6 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-21.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Intellia Therapeutics expected to grow at an attractive rate?
  • Unable to compare Intellia Therapeutics's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Intellia Therapeutics's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
  • Intellia Therapeutics's revenues are expected to decrease over the next 1-3 years, this is below the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:NTLA Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:NTLA Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts -21.3%
NasdaqGM:NTLA Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 6 Analysts -0.5%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 22.6%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 17.5%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.9%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:NTLA Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:NTLA Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 30 -134 -256 2
2022-12-31 34 -101 -207 5
2021-12-31 33 -138 -189 4
2020-12-31 35 -88 -140 6
2019-12-31 33 -71 -110 6
NasdaqGM:NTLA Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 33 -65 -86
2018-12-31 30 -61 -85
2018-09-30 29 -74 -90
2018-06-30 29 -78 -83
2018-03-31 27 -72 -76
2017-12-31 26 -65 -68
2017-09-30 25 -58 -54
2017-06-30 23 -49 -46
2017-03-31 21 34 -38
2016-12-31 16 36 -32
2016-09-30 13 45 -26
2016-06-30 9 49 -22

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Intellia Therapeutics is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Intellia Therapeutics's revenue is expected to decrease over the next 1-3 years, this is not considered high growth.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:NTLA Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below

All data from Intellia Therapeutics Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:NTLA Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 -3.32 -3.11 -3.53 2.00
2022-12-31 -3.30 -2.68 -3.76 4.00
2021-12-31 -3.12 -2.54 -3.90 6.00
2020-12-31 -2.91 -2.14 -3.75 6.00
2019-12-31 -2.48 -1.90 -3.08 6.00
NasdaqGM:NTLA Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 -1.96
2018-12-31 -1.98
2018-09-30 -2.16
2018-06-30 -2.08
2018-03-31 -2.02
2017-12-31 -1.88
2017-09-30 -1.55
2017-06-30 -1.33
2017-03-31 -1.22
2016-12-31 -1.42
2016-09-30 -1.92
2016-06-30 -4.54

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Intellia Therapeutics will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Intellia Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Intellia Therapeutics has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

NTLA Past Performance

  How has Intellia Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Intellia Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Intellia Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Intellia Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Intellia Therapeutics's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Intellia Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Intellia Therapeutics Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:NTLA Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 33.40 -85.93 35.32
2018-12-31 30.43 -85.34 32.19
2018-09-30 29.22 -90.24 33.69
2018-06-30 29.13 -82.89 31.14
2018-03-31 27.37 -76.27 29.70
2017-12-31 26.12 -67.54 28.03
2017-09-30 25.08 -54.14 22.93
2017-06-30 22.63 -46.27 21.92
2017-03-31 20.92 -37.58 19.28
2016-12-31 16.48 -31.63 16.80
2016-09-30 12.55 -26.32 14.49
2016-06-30 9.36 -21.85 11.32
2016-03-31 6.54 -17.99 10.42
2015-12-31 6.04 -12.40 8.28
2015-09-30 4.35 -14.37 8.19
2014-12-31 -14.31 3.57

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Intellia Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Intellia Therapeutics has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Intellia Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Intellia Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Intellia Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

NTLA Health

 How is Intellia Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Intellia Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Intellia Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Intellia Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Intellia Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 15.6x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Intellia Therapeutics Company Filings, last reported 1 month ago.

NasdaqGM:NTLA Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 264.34 19.51 296.58
2018-12-31 277.92 0.00 314.06
2018-09-30 263.27 0.00 293.25
2018-06-30 279.34 0.00 305.54
2018-03-31 295.50 0.00 327.78
2017-12-31 300.60 0.00 340.68
2017-09-30 175.85 0.00 222.26
2017-06-30 187.59 0.00 241.05
2017-03-31 199.88 0.00 257.55
2016-12-31 209.84 0.00 273.06
2016-09-30 218.12 0.00 290.62
2016-06-30 223.60 0.00 300.69
2016-03-31 61.48 0.00 64.19
2015-12-31 67.36 0.00 75.82
2015-09-30 72.26 0.00 82.61
2014-12-31 7.57 0.00 9.85
  • Intellia Therapeutics's level of debt (7.4%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if Intellia Therapeutics's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Intellia Therapeutics has sufficient cash runway for more than 3 years based on current free cash flow.
  • Intellia Therapeutics has sufficient cash runway for 2.5 years if free cash flow continues to grow at historical rates of 74% each year.
X
Financial health checks
We assess Intellia Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Intellia Therapeutics has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

NTLA Dividends

 What is Intellia Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Intellia Therapeutics dividends. Estimated to be 0% next year.
If you bought $2,000 of Intellia Therapeutics shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Intellia Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Intellia Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:NTLA Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 19 Stocks 2.4%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2000 Stocks 2.5%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:NTLA Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Intellia Therapeutics has not reported any payouts.
  • Unable to verify if Intellia Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Intellia Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Intellia Therapeutics has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Intellia Therapeutics's dividends in 3 years as they are not expected to pay a notable one for United States of America.
X
Income/ dividend checks
We assess Intellia Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Intellia Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Intellia Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

NTLA Management

 What is the CEO of Intellia Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
John Leonard
COMPENSATION $9,708,330
AGE 61
TENURE AS CEO 1.3 years
CEO Bio

Dr. John M. Leonard, M.D., has been a Director at IQVIA Holdings Inc. since February 2015 and has been its Lead Director since July 25, 2018. Dr. Leonard has been the President and Chief Executive Officer of Intellia Therapeutics Inc. since January 1, 2018. He served as Executive Vice President of Research & Development at Intellia since January 13, 2017 and served as its Chief Medical Officer since joining in July 2014 until January 13, 2017. Dr. Leonard is an Executive Partner at Tyree & D'Angelo Partners. He spent over 22 years at AbbVie and Abbott Laboratories from 1992, until his retirement from AbbVie in 2013. Dr. Leonard served as the Chief Scientific Officer and Senior Vice President at AbbVie Inc. Dr. Leonard served as a Senior Vice President of Pharmaceuticals, Research and Development at AbbVie Inc. He served as Senior Vice President of Pharmaceuticals, Research and Development at Abbott Diabetes Care, Inc. from February 2008 to 2012. Dr. Leonard served as Senior Vice President of Pharmaceuticals, Research and Development at Abbott Laboratories since February 2008. While serving as the Global Head of Pharmaceutical R&D at Abbott Laboratories, he oversaw the development of numerous novel therapeutics. His ground-breaking work with HIV protease inhibitors Norvir and Kaletra led to new treatment paradigms for AIDS, while his years of work with Humira made it the all-time top-selling drug worldwide. Dr. Leonard served as Vice President of Global Medical & Scientific Affairs at Abbott Laboratories. He served as Vice President of Global Pharmaceutical Drug Development at Abbott Laboratories since 2001 and also Vice President of Pharmaceutical Development from 1999 to 2001, Divisional Vice President, Pharmaceutical Development, Pharmaceutical Products Research and Development from 1998 to 1999 and served as its Corporate Officer since 1999. Since joining Abbott in 1992 as Head of the Antiviral Venture in the Pharmaceutical Products Division, Dr. Leonard has held several positions in the same division. Prior to joining Abbott, he served as Senior Director for Clinical Research at G.H. Besselaar Associates. He served as Chairman of the Supervisory Board of Abbott Germany. Dr. Leonard serves as Director of Quintiles Transnational, Inc. He has been a Director of Quintiles Transnational Holdings Inc. since February 5, 2015. He served as a Director of Intellia Therapeutics Inc. Dr. Leonard was a Director of Chimerix Inc. until June 20, 2018. He has been a Director of Quintiles Transnational Holdings Inc. since February 5, 2015. Dr. Leonard serves as a Director of Biotechnology Innovation Organization. He is a Director of the National Association for Biomedical Research (NABR). Dr. Leonard served as Member of Scientific Advisory Board at Verseon Corporation until 2019. He served as a Director of Vitae Pharmaceuticals, Inc. from July 29, 2015 to October 25, 2016. Dr. Leonard served as a Board Member of a number of organizations including Reata Pharmaceutical. He served as a Director of Arisaph Pharmaceuticals, Inc., since 2007. Dr. Leonard has a 30-year career in pharmaceutical R&D, healthcare management, research and development and medicine. He is among the leading R&D executives who have not only introduced breakthrough medicines, but also guided their development into mega-blockbuster drugs. Dr. Leonard is board certified in Internal Medicine and is licensed to practice in Illinois and Maryland. He completed an Internship and Residency in Internal Medicine at Stanford University Hospital followed by a Postdoctoral Fellowship in Molecular Virology at the National Institute of Allergy and Infectious Diseases at the National Institutes of Health. Dr. Leonard earned an MD from Johns Hopkins University in Baltimore, MD. and BA degree in biochemistry from the University of Wisconsin at Madison.

CEO Compensation
  • John's compensation has increased whilst company is loss making.
  • John's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Intellia Therapeutics management team in years:

3.6
Average Tenure
48
Average Age
  • The tenure for the Intellia Therapeutics management team is about average.
Management Team

John Leonard

TITLE
President
COMPENSATION
$10M
AGE
61
TENURE
1.3 yrs

Glenn Goddard

TITLE
Executive VP & CFO
COMPENSATION
$2M
AGE
47
TENURE
0.6 yrs

José Rivera

TITLE
Executive VP & General Counsel
COMPENSATION
$3M
AGE
52
TENURE
4.8 yrs

Andrew Schiermeier

TITLE
Executive Vice President of Corporate Strategy & Development
COMPENSATION
$3M
AGE
48
TENURE
2.3 yrs

Nessan Bermingham

TITLE
Founder & Member of Scientific Advisor Board
COMPENSATION
$11M
AGE
45
TENURE
5 yrs

Rachel Haurwitz

TITLE
Co-Founder
COMPENSATION
$312K
AGE
32
TENURE
5 yrs

Andy May

TITLE
Founder and Member of Scientific Advisor Board

Jennifer Doudna

TITLE
Founder & Member of Scientific Advisor Board
AGE
54

Derrick Rossi

TITLE
Founder & Member of Scientific Advisor Board

Rodolphe Barrangou

TITLE
Founder & Member of Scientific Advisor Board
Board of Directors Tenure

Average tenure and age of the Intellia Therapeutics board of directors in years:

4.1
Average Tenure
61
Average Age
  • The tenure for the Intellia Therapeutics board of directors is about average.
Board of Directors

Perry Karsen

TITLE
Chairman
COMPENSATION
$428K
AGE
63
TENURE
3.1 yrs

John Leonard

TITLE
President
COMPENSATION
$10M
AGE
61
TENURE
4.8 yrs

Nessan Bermingham

TITLE
Founder & Member of Scientific Advisor Board
COMPENSATION
$11M
AGE
45

Andy May

TITLE
Founder and Member of Scientific Advisor Board

Jennifer Doudna

TITLE
Founder & Member of Scientific Advisor Board
AGE
54
TENURE
4.1 yrs

Derrick Rossi

TITLE
Founder & Member of Scientific Advisor Board
TENURE
4.1 yrs

Rodolphe Barrangou

TITLE
Founder & Member of Scientific Advisor Board

Luciano Marraffini

TITLE
Founder & Member of Scientific Advisor Board

Erik Sontheimer

TITLE
Founder & Member of Scientific Advisor Board

Jean-François Formela

TITLE
Director
COMPENSATION
$351K
AGE
61
TENURE
5 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Intellia Therapeutics insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
12. Mar 19 Buy Andrew Schiermeier Individual 06. Mar 19 06. Mar 19 7,500 $16.00 $117,875
X
Management checks
We assess Intellia Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Intellia Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

NTLA News

Simply Wall St News

Need To Know: Intellia Therapeutics, Inc. (NASDAQ:NTLA) Insiders Have Been Buying Shares

In the last twelve months, the biggest single purchase by an insider was when Andrew Schiermeier bought US$118k worth of shares at a price of US$16.00 per share. … That means that an insider was happy to buy shares at above the current price of US$14.82. … As a general rule, we feel more positive about a stock when an insider has bought shares at above current prices, because that suggests they viewed the stock as good value, even at a higher price

Simply Wall St -

If You Had Bought Intellia Therapeutics (NASDAQ:NTLA) Stock A Year Ago, You'd Be Sitting On A 50% Loss, Today

Intellia Therapeutics isn't a profitable company, so it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). … When a company doesn't make profits, we'd generally expect to see good revenue growth. … That's because it's hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit.

Simply Wall St -

What You Must Know About Intellia Therapeutics Inc's (NASDAQ:NTLA) Financial Strength

However, the trade-off is NTLA will have to adhere to stricter debt covenants and have less financial flexibility. … Is NTLA growing fast enough to value financial flexibility over lower cost of capital. … Debt capital generally has lower cost of capital compared to equity funding

Simply Wall St -

Was Intellia Therapeutics Inc's (NASDAQ:NTLA) Earnings Decline Part Of A Broader Industry Downturn?

Today I will take a look at Intellia Therapeutics Inc's (NASDAQ:NTLA) most recent earnings update (31 March 2018) and compare these latest figures against its performance over the past few years, as well as how the rest of the biotechs industry performed. … Was NTLA's recent earnings decline worse than the long-term trend and the industry. … NTLA is loss-making, with the most recent trailing twelve-month earnings of -US$76.27m (from 31 March 2018), which compared to last year has become.

Simply Wall St -

Intellia Therapeutics Inc (NASDAQ:NTLA): Set To Experience A Decrease In Earnings?

The latest earnings update Intellia Therapeutics Inc's (NASDAQ:NTLA) released in December 2017 showed company earnings became less negative compared to the previous year's level as a result of recent tailwinds Below is a brief commentary on my key takeaways on how market analysts view Intellia Therapeutics's earnings growth outlook over the next few years and whether the future looks brighter. … Check out our latest analysis for Intellia Therapeutics Analysts' outlook for the upcoming year seems pessimistic, with earnings becoming even more negative, reaching -US$88.29M in 2019. … This means, we can assume Intellia Therapeutics will chip away at a rate of -15.57% every year for the next few years.

Simply Wall St -

Does Intellia Therapeutics Inc's (NTLA) Past Performance Indicate A Weaker Future?

Today I will examine Intellia Therapeutics Inc's (NASDAQ:NTLA) latest earnings update (30 September 2017) and compare these figures against its performance over the past couple of years, in addition to how the rest of NTLA's industry performed. … Intellia Therapeutics's most recent twelve-month earnings -$54.1M, which, in comparison to last year’s figure, has become more negative. … Though Intellia Therapeutics's past data is helpful, it is only one aspect of my investment thesis.

Simply Wall St -

NTLA Company Info

Description

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, and primary hyperoxaluria. Its ex vivo pipeline includes proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune diseases; partnered programs focused on chimeric antigen receptor T cells and hematopoietic stem cells; and acute myeloid leukemia. Intellia Therapeutics, Inc. has collaboration agreement with Novartis Institutes for BioMedical Research, Inc.; Ospedale San Raffaele; Regeneron Pharmaceuticals, Inc.; and Caribou Biosciences, Inc. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.

Details
Name: Intellia Therapeutics, Inc.
NTLA
Exchange: NasdaqGM
Founded: 2014
$710,804,883
45,710,925
Website: http://www.intelliatx.com
Address: Intellia Therapeutics, Inc.
40 Erie Street,
Suite 130,
Cambridge,
Massachusetts, 02139,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM NTLA Common Stock Nasdaq Global Market US USD 06. May 2016
DB 38I Common Stock Deutsche Boerse AG DE EUR 06. May 2016
LSE 0JBU Common Stock London Stock Exchange GB USD 06. May 2016
Number of employees
Current staff
Staff numbers
211
Intellia Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/20 03:13
End of day share price update: 2019/05/17 00:00
Last estimates confirmation: 2019/05/08
Last earnings filing: 2019/05/02
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.